Bayer seeks to reclaim losses from Chiron on Rapidpoint 400
This article was originally published in Clinica
Executive Summary
Bayer is claiming that US biotechnology company Chiron failed to disclose technical faults associated with the Rapidpoint 400 blood gas analyser when Bayer acquired Chiron's diagnostics arm in 1998 (see Clinica No 826, p 1). Bayer recalled the product in early 1999, press reports state, and now, having relaunched the product, has filed suit in a Delaware district court (civil case 02-80). The claim for damages runs into several million dollars. The Wall Street Journal suggests a claim figure of $13.5 million.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.